GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BrightPath Biotherapeutics Co Ltd (TSE:4594) » Definitions » Interest Expense

BrightPath Biotherapeutics Co (TSE:4594) Interest Expense : 円-1.40 Mil (TTM As of Sep. 2024)


View and export this data going back to 2015. Start your Free Trial

What is BrightPath Biotherapeutics Co Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. BrightPath Biotherapeutics Co's interest expense for the three months ended in Sep. 2024 was 円 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Sep. 2024 was 円-1.40 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. BrightPath Biotherapeutics Co's Operating Income for the three months ended in Sep. 2024 was 円 0.00 Mil. BrightPath Biotherapeutics Co's Interest Expense for the three months ended in Sep. 2024 was 円 0.00 Mil. BrightPath Biotherapeutics Co has no long-term debt (1). The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

(1) Note: An indication of "no long-term debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

BrightPath Biotherapeutics Co Interest Expense Historical Data

The historical data trend for BrightPath Biotherapeutics Co's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BrightPath Biotherapeutics Co Interest Expense Chart

BrightPath Biotherapeutics Co Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Interest Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only - -9.10 -0.36 -0.06 -1.40

BrightPath Biotherapeutics Co Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Sep24
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - -1.40 -

BrightPath Biotherapeutics Co Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was 円-1.40 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BrightPath Biotherapeutics Co  (TSE:4594) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

BrightPath Biotherapeutics Co's Interest Expense for the three months ended in Sep. 2024 was 円0.00 Mil. Its Operating Income for the three months ended in Sep. 2024 was 円0.00 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Sep. 2024 was 円0.00 Mil.

BrightPath Biotherapeutics Co's Interest Coverage for the quarter that ended in Sep. 2024 is calculated as

BrightPath Biotherapeutics Co had no long-term debt (1).

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

BrightPath Biotherapeutics Co Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BrightPath Biotherapeutics Co Ltd (TSE:4594) » Definitions » Interest Expense
Comparable Companies
TSE:4881 TSE:2385 TSE:4591 TSE:2342 TSE:4596 TSE:6190 TSE:4884 TSE:4570 TSE:4576 TSE:130A VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX XBRU:UCB ALNY ONC BNTX XKRX:068270
Traded in Other Exchanges
N/A
Address
2-2-4 Kojimachi, Kojimachi Central Building 7th Floor, Chiyoda-ku, Tokyo, JPN
Website
https://www.brightpathbio.com
BrightPath Biotherapeutics Co Ltd is a biopharmaceutical venture company. It is engaged in developing novel cancer immunotherapeutics. Its products include two candidate products: ITK-1 and GRN-1201 which are in the clinical trial stage.

BrightPath Biotherapeutics Co Headlines

No Headlines